University College, London

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University College, London sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 4 currently recruiting early-phase tilt upper quartile by trial count

University College, London: 8 sponsored US clinical trials, 4 recruiting.

University College, London sponsors 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dentatorubral-Pallidoluysian Atrophy, with 1 trials.

Upper-quartile sponsor footprint

University College, London sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 1

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

NCT06372821
RECRUITING

Dentatorubral-pallidoluysian Atrophy Natural History and Biomarkers Study

NCT06273150
RECRUITING Phase 3

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

NCT04685616
RECRUITING

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

NCT02855476
ACTIVE NOT RECRUITING NA

Prostate Imaging Using MRI +/- Contrast Enhancement

NCT04571840
ACTIVE NOT RECRUITING Phase 1

Gene Therapy for Haemophilia A.

NCT03001830
TERMINATED Phase 1

A Factor IX Gene Therapy Study (FIX-GT)

NCT03369444
TERMINATED NA

Evaluating Dietary Intervention Before surgicaL Treatment for Epilepsy

NCT02261753

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 3 1

Therapeutic Areas

Dentatorubral-Pallidoluysian Atrophy 1
Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder) 1
Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder) 1
Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder) 1
Huntington's Disease 1
Hemophilia A 1
Hodgkin Lymphoma 1
Alzheimer Disease 1
Prostate Cancer 1

What is open in the University College, London pipeline

4 recruiting of 8 indexed (50% open).

Phase mix: 1 late (III/IV) vs 3 early (I/II) (early-phase heavy).

Top condition: Dentatorubral-Pallidoluysian Atrophy (1 trial), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University College, London: open-pipeline peers nationwide

Peers matched on 8 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

University College, London sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0246810 0%20%40%60% Total trials Recruiting share University College, LondonAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1200 Pharma1ST Biotherapeutics3ive Labs60 Degrees Pharmaceuticals
University College, London sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University College, London sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University College, London page

8 registered trials is a research-attention snapshot, not an endorsement of University College, London or any single study.

  • 4 of University College, London's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Dentatorubral-Pallidoluysian Atrophy is the condition University College, London studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dentatorubral-Pallidoluysian Atrophy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University College, London pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.